Etesevimab

Generic name: etesevimab [ ET-e-SEV-a-mib ]
Dosage form: intravenous solution (700 mg/20 mL)

What is etesevimab?

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

Etesevimab is an experimental medicine being studied for use in treating conditions caused by coronavirus. It is not yet known if etesevimab is safe and effective.

Etesevimab and bamlanivimab are also for use in people who have been exposed to COVID-19 and:

• are not fully vaccinated against COVID-19; or

• are vaccinated but may not have built up enough immunity (because they have certain diseases or use certain medicines), and have been or may be exposed to people who are infected with COVID-19.

Etesevimab and bamlanivimab are for use in adults and children of all ages, including newborns.

The risk of COVID-19 symptoms becoming severe may be higher in people who:

• are overweight;

• have chronic kidney disease;

• have diabetes;

• have a weak immune system (caused by disease or by using certain medicine);

• have sickle cell disease;

• have a heart problem or high blood pressure;

• have a neurodevelopmental disorder such as cerebral palsy;

• have asthma or other chronic breathing disorder; or

• have a tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19).

There also may be a higher risk of severe COVID-19 symptoms in pregnant women and in adults who are 65 and older.

Etesevimab and bamlanivimab are not approved to treat or prevent coronavirus or COVID-19. However, these medicines may help prevent the need for emergency medical care or admission to a hospital because of COVID-19. Bamlanivimab with etesevimab is not authorized for use in people who are already in the hospital or receiving supplemental oxygen for COVID-19.

Etesevimab may also be used for purposes not listed in this medication guide.

Warnings

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

Before taking this medicine

Etesevimab and bamlanivimab are not authorized for use in states or territories where certain variants of COVID-19 may be resistant to these medicines. Tell your doctor where you've lived or traveled to in the past 2 weeks.

Tell your doctor if:

• you had a COVID-19 vaccine;

• you have any allergy;

• you have any serious or chronic disease; or

• you are pregnant or breastfeeding.